In refractory leukemia, IV busulfan plus cyclophosphamide may be a valid alternative
the ONA take:
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative to cyclophosphamide plus total body irradiation conditioning regimen for patients with refractory acute myeloid leukemia, according to a new study published online ahead of print in the The Lancet Haematology.
For the study, researchers analyzed data from 514 patients with refractory acute myeloid leukemia in active phase who had received intravenous busulfan plus cyclophosphamide and 338 patients who had received cyclophosphamide plus total body irradiation. All patients then received allogenic hematopoietic stem-cell transplantation from an HLA-identical sibling or an unrelated donor.
Results showed that 2-year overall survival and 2-year leukemia-free survival did not differ between the 2 groups. Researchers found that the main reasons for non-relapse mortality were graft-versus-host disease and infection.
The findings suggest that intravenous busulfan plus cyclophosphamide may be especially preferable for transplant centers that do not have access to radiation facilities.
Intravenous busulfan plus cyclophosphamide may be a valid and efficient alternative for patients with refractory acute myeloid leukemia.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|